Skip to main content

Table 5 ORs (95% CIs) for a 30% increment in baseline biomarker, and in year 1 to baseline biomarker ratio (change), based on cases occurring after year 1 and disease-specific controls, from the WHI estrogen plus progestin and estrogen-alone HT trials

From: Proteomic risk markers for coronary heart disease and stroke: validation and mediation of randomized trial hormone therapy effects on these diseases

CHD
Modeled variables Na Biomarker values included
Baseline only Baseline + change
Treatmenta 491 1.14 (0.79, 1.66)b 1.16 (0.80, 1.68)
B2M baseline   1.22 (1.06, 1.40) 1.13 (0.95, 1.34)
B2M change    1.12 (0.96, 1.32)
Triala   1.09 (0.74, 1.59) 1.08 (0.74, 1.59)
Treatmenta 489 1.21 (0.83, 1.75)b 1.24 (0.83, 1.84)
ORM1 baseline   1.00 (0.87, 1.16) 0.98 (0.82, 1.18)
ORM1 change    1.03 (0.87, 1.24)
Triala   1.03 (0.71, 1.51) 1.03 (0.71, 1.51)
Treatmenta 395 1.11 (0.73, 1.68)b 1.11 (0.73, 1.68)
THBS1 baseline   0.95 (0.91, 1.00) 0.95 (0.89, 1.01)
THBS1 change    1.01 (0.95, 1.07)
Triala   0.96 (0.66, 1.39) 0.92 (0.60, 1.41)
Treatmenta 489 1.19 (0.82, 1.72)b 1.26 (0.86 1.85)
CFD baseline   1.09 (0.95, 1.24) 0.93 (0.73 1.19)
CFD change    1.20 (0.94 1.52)
Triala   1.03 (0.73, 1.46) 1.06 (0.72 1.56)
Treatmenta 479 1.18 (0.81, 1.72)b 0.96 (0.62, 1.49)
IGFBP1 baseline   1.01 (0.96, 1.06) 0.97 (0.90, 1.03)
IGFBP1 change    1.07 (0.99, 1.14)
Triala   0.98 (0.67, 1.44) 1.01 (0.69, 1.50)
Stroke
Modeled variables N a Biomarker values included
   Baseline only Baseline + change
Treatmenta 552 1.84 (1.28, 2.64)b 1.87 (1.30, 2.70)
B2M baseline   1.10 (0.97, 1.23) 0.99 (0.86, 1.14)
B2M change    1.24 (1.03, 1.50)
Triala   1.10 (0.76, 1.59) 1.13 (0.78, 1.64)
Treatmenta 508 1.67 (1.14, 2.44)b 1.57 (1.05, 2.33)
IGFBP2 baseline   1.09 (1.00, 1.18) 1.14 (1.00, 1.31)
IGFBP2 change    0.94 (0.84, 1.06)
Triala   1.09 (0.74, 1.60) 1.10 (0.75, 1.61)
Treatmenta 524 1.77 (1.22, 2.57)b 1.74 (1.20, 2.53)
IGFBP4 baseline   1.18 (1.04, 1.34) 1.10 (0.93, 1.30)
IGFBP4 change    1.10 (0.94, 1.28)
Triala   1.08 (0.75, 1.30) 1.10 (0.75, 1.61)
Treatmenta 474 1.60 (1.08, 2.37)b 1.60 (1.08, 2.37)
IGFBP6 baseline   0.99 (0.90, 1.09) 0.99 (0.89, 1.11)
IGFBP6 change    0.99 (0.91, 1.09,)
Triala   1.12 (0.75, 1.66) 1.11 (0.75, 1.66)
Treatmenta 526 1.74 (1.20, 2.51)b 1.74 (1.20, 2.51)
HPX baseline   1.06 (0.88, 1.28) 1.07 (0.84, 1.36)
HPX change    0.99 (0.77, 1.29)
Triala   1.11 (0.76, 1.62) 1.11 (0.76, 1.62)
  1. aN, total number of cases plus controls; Treatment, 1 - active; 0 - placebo; Trial, 1 - E + P trial (no hysterectomy), 0 - E-alone trial (post-hysterectomy).
  2. bAll analyses include baseline age, prior history of study disease, systolic and diastolic blood pressure, smoking history, treated diabetes history, prior HT use, and body mass index as regression variables to control confounding.
Back to article page

Genome Medicine

ISSN: 1756-994X

Contact us